Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification

Juhlin, C. Christofer; Villablanca, Andrea; Sandelin, Kerstin; Haglund, Felix; Nordenström, Jörgen; Forsberg, Lars; Bränström, Robert; Obara, Takao; Arnold, Andrew; Larsson, Catharina; Höög, Anders

doi:10.1677/erc-07-0021

Cited by 114 publications

(112 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results have been reported by other workers. 59,60 However, in our own experience, loss of parafibromin staining has been observed in some adenomas unassociated with the HPT-JT syndrome, whereas some PT-CAs have been positive. 61 On the basis of a detailed literature review, 46% of PT-CAs have been reported as parafibromin negative, whereas 88% of cases have been reported as negative and/or weakly positive.…”

Section: Parathyroid Carcinomamentioning

confidence: 62%

Parathyroid tumors and related disorders

2011

View full text Add to dashboard Cite

Primary hyperparathyroidism (P-HPT) is a common endocrine disorder that occurs as a result of adenomas (80-85%), hyperplasias (10-15%) or carcinomas (o1%) of the parathyroid glands. Molecular genetic analyses of heritable P-HPT syndromes have provided considerable insight into the understanding of sporadic parathyroid tumors and hyperplasias. This review will focus on the criteria for classification of parathyroid proliferative disorders and will highlight our understanding of these lesions at the molecular level. Advances in radiological imaging techniques together with the rapid intraoperative parathyroid hormone assay will be reviewed with respect to current treatment approaches for P-HPT.

show abstract

Section: Parathyroid Carcinomamentioning

confidence: 62%

Parathyroid tumors and related disorders

2011

View full text Add to dashboard Cite

show abstract

“…28 A recent study found that 68% (15 of 22) of unequivocal parathyroid carcinomas showed reduced expression of parafibromin in contrast to the positive parafibromin staining of all 25 parathyroid adenomas used as control. 35 The authors 35 concluded that parafibromin immunostaining was a useful additional marker. They also found that benign tumors stained positive, whereas reduced expression could indicate malignancy or rare cases of adenomas, possibly with HRPT2 mutations.…”

Section: Discussionmentioning

confidence: 99%

Defining a molecular phenotype for benign and malignant parathyroid tumors

Fernández-Ranvier

Khanafshar

Tacha

et al. 2009

Cancer

101

View full text Add to dashboard Cite

BACKGROUND:It is frequently difficult to establish histologically whether a parathyroid tumor is a parathyroid carcinoma, parathyromatosis, or an atypical adenoma. The authors asked whether these tumors have a distinctive molecular profile, whether benign tumors could be distinguished from malignant tumors, and whether parathyromatosis is a low‐grade parathyroid carcinoma or is benign tissue that can invade other organs.METHODS:Samples of parathyroid carcinoma, atypical adenoma, parathyromatosis, parathyroid adenoma, and hyperplasia were obtained for tissue microarray studies. The molecular expression of genes involved in parathyroid tumor progression (HRPT2 [“parafibromin”], galectin‐3, Ki‐67, Rb, p27, and mdm‐2) was investigated by immunohistochemistry.RESULTS:Complete loss of parafibromin expression was seen in 5 of 16 (31.3%) parathyroid carcinomas; all parathyromatosis, atypical adenomas, adenomas, and hyperplasia stained positive for parafibromin. Loss of Rb expression was seen in 5 (33.3%) of 15 parathyroid carcinomas and 1 (7.1%) of 14 parathyroid hyperplasias; all parathyromatosis, atypical adenomas, and adenomas stained positive. Galectin‐3 stained strongly positive in 14 (93.3%) of 15 parathyroid carcinomas, and positive in 3 (18.7%) of 16 cases of parathyromatosis, 2 (100%) of 2 atypical adenomas, 1 (5.6%) of 18 adenomas, and 2 (14.3%) of 14 hyperplasias. The Ki‐67 proliferative index was high in 9 (60%) of 15 parathyroid carcinomas, 1 (6.7%) of 15 cases of parathyromatosis, 1 (5.6%) of 18 adenomas, and no atypical adenomas or hyperplasia. P27 and mdm‐2 protein expression did not differ appreciably among the tumor types.CONCLUSIONS:No single diagnostic marker currently determines whether a parathyroid tumor is a parathyroid carcinoma, but loss of parafibromin and Rb expression, and overexpression of galectin‐3, generally distinguish parathyroid carcinoma from other parathyroid tumors. Parathyromatosis does not appear to be a low‐grade parathyroid carcinoma. Cancer 2009. © 2009 American Cancer Society.

show abstract

“…These new markers include parafibromin, expression of Rb, Ki-67 and Galectin-3. Unfortunately, none of these has enough sensitivity and specificity on its own, therefore their results need to be interpret the results jointly [3,16].…”

Section: C4mentioning

confidence: 99%

Parathyroid cancer — difficult diagnosis — a case report

et al. 2016

View full text Add to dashboard Cite

Parathyroid cancer is a rare disorder of unclear etiology that is difficult to diagnose and treat. It is most often diagnosed incidentally based on multi-organ non-specific symptoms of hypercalcemia as a consequence of parathyroid hormone oversecretion. We present a case of a male with primary hyperparathyroidism who was diagnosed with parathyroid cancer ectopically located in the mediastinum only after the third surgery. However, due to chronic hypercalcemia, problems with localization and a bad clinical condition, the patient was not able to undergo a radical resection and one year after the first pathological fracture died. Taking into consideration the whole clinical picture we want to emphasize the need to apply comprehensive differential diagnosis of hypercalcemia and localization diagnosis of parathyroid tissue with a use of MIBI scintigraphy accompanied by the computed tomography and magnetic resonance imaging, as the most specific diagnostic tools employed in this pathology.

show abstract

Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification

Cited by 114 publications

References 33 publications

Parathyroid tumors and related disorders

Parathyroid tumors and related disorders

Defining a molecular phenotype for benign and malignant parathyroid tumors

Parathyroid cancer — difficult diagnosis — a case report

Contact Info

Product

Resources

About